Boston-based Keryx Biopharmaceuticals has reported what it calls "progress" in the launch of its drug for dialysis patients, called Auryxia, in recent months, including expanded insurance coverage in the U.S., success in contacting potential prescribers and likely European approval in coming months. Keryx , which moved its headquarters to Boston last year from New York City, reported Auryxia sales of just $1.8 million in the second quarter since the drug's launch.